Clinical trial NCT02494479 (phase 2, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: prurisol, placebo
SMILES: NC1=NC(NC2CC2)=C2N=CN([C@@H]3C[C@H](COC(=O)CO)C=C3)C2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or non-pregnant female adults aged 18 years with a clinical diagnosis of stable
             (at least 6 months) plaque psoriasis, not including scalp or intertriginous areas.

          -  The extent of psoriasis must meet all of the following three (3) criteria:

               -  Total Body Surface Area (BSA) affected by plaque psoriasis of 10% to 20%
                  inclusive

               -  Investigator's Global Assessment (IGA) score of the severity of psoriasis of 2 or
                  3 (5- point ordinal scale)

               -  Identification of a target psoriatic lesion with a score of 3 on the Target
                  Lesion Assessment scale (5-point ordinal scale) for Scaling. (Other psoriatic
                  lesions may have lower scaling scores.)

          -  Females of reproductive potential must not be pregnant

          -  Female subjects with reproductive potential, if sexually active, must agree to use
             reliable means of contraception

          -  The subject must agree to avoid prolonged exposure to the sun and avoid the use of
             tanning booths or other ultraviolet light sources during the study.

          -  The subject must provide signed and dated written informed consent to participate in
             the clinical study.

        Exclusion Criteria:

          -  1. Females of reproductive potential who are not using reliable contraception.

          -  Presence of any non-psoriatic uncontrolled (in the Investigator's medical opinion)
             systemic disease. i

          -  Unstable forms of psoriasis, e.g. guttate, erythrodermic, exfoliative, palmoplantar,
             nail, or pustular.

          -  Use within 6 months of biologic treatment for psoriasis

          -  Use within 24 months of chemotherapy or radiation therapy.

          -  Use within 2 months of any systemic immunosuppressive therapy.

          -  Use within 1 month of (1) systemic corticosteroids, (2) systemic antibiotics, (3)
             systemic antipsoriasis treatments (e.g. methotrexate, corticosporin, hydroxyurea), (4)
             PUVA therapy, (5) UVB, (6) systemic anti-inflammatory treatment.

          -  Use within 2 weeks of topical antipsoriasis drugs or topical corticosteroids or
             topical retinoids.

          -  Presence of a condition (e.g., history of frequent consumption of substantial
             quantities of alcohol, or an untreated psychiatric condition) that makes it unlikely
             that the requirements of the protocol will be completed.

          -  History of any previous use of a Tumor Necrosis Factor (TNF) blocker or other
             immunomodulating drug as therapy for psoriasis within the 6 months prior to screening.

          -  History of any allergic reaction to any formulation of abacavir.

          -  Previous treatment with any abacavir-containing product, e.g., Ziagen®, Epzicom®, or
             Trizivir®.